Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis · 2024
DOI: 10.1016/j.jpba.2024.116116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2024. Verfasst von Shankha Dey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Rats, Wistar, Tandem Mass Spectrometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
EC5026 is a novel soluble epoxide hydrolase inhibitor being developed clinically to treat neuropathic pain and inflammation. In the current study, we employed the LC-ESI-Q-TOF-MS/MS technique to identify four in-vivo phase-I metabolites of EC5026 in rat model, out of which three were found to be novel. The identified metabolites include aliphatic hydroxylation, di-hydroxylation, terminal desaturation, and carboxylation. No phase-II metabolites were found. The pharmacokinetic profile of identified metabolites was established after a single oral dose of EC5026 to Wistar rats. The Tmax of the drug and metabolites were found to be in the range of 1-2 hours and 4-12 hours, respectively. The major metabolites M1 and M2 were found to have more than 2-fold (263.87% AUC) and equivalent exposure (96.33% AUC) compared to the parent drug, respectively. Further, the docking study revealed that the mono-hydroxylated and terminally desaturated metabolites possess better binding affinity than the parent drug. Therefore, these metabolites may hold sEH inhibition potential and can be followed through future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India.
- ICMR-National Institute of Cancer Prevention and Research, I-7, Sector-39, Noida 201301, India.
- Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, India. Electronic address: swapnil@niperguwahati.in.
Zitieren
APA
Dey, S., Biradar, R., Mane, S. S., Kunnath Shaji, A., Das, A. P., Agarwal, S. M., & Dengale, S. J. (2024). Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116116
Vancouver
Dey S, Biradar R, Mane SS, Kunnath Shaji A, Das AP, Agarwal SM, et al. Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2024. doi:10.1016/j.jpba.2024.116116
BibTeX
@article{Dey2024,
author = {Dey, Shankha and Biradar, Rushikesh and Mane, Sayalee Sanjay and Kunnath Shaji, Anandhu and Das, Agneesh Pratim and Agarwal, Subhash Mohan and Dengale, Swapnil Jayant},
title = {Identification and characterization of the in-vivo metabolites of the novel soluble epoxide hydrolase inhibitor EC5026 using liquid chromatography quadrupole time of flight mass spectrometry},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2024},
doi = {10.1016/j.jpba.2024.116116}
}
EUVIMED